Georg Richtig

13PUBLICATIONS
26CO-AUTHORS
Biological network analysisMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 07, 2023
Predatory journals: Perception, impact and use of Beall's list by the scientific community-A bibliometric big data study.

Georg Richtig, Marina Berger, Max Koeller

|Aug 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors.

Matthew Dankner, Yifan Wang, Rouhi Fazelzad

|Mar 13, 2019
Hedgehog pathway proteins SMO and GLI expression as prognostic markers in head and neck squamous cell carcinoma.

Georg Richtig, Alena M Aigelsreiter, Martin Asslaber

|Oct 02, 2018
Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.

Georg Richtig, Christoph Hoeller, Martin Wolf

|Nov 10, 2017
SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types.

Georg Richtig, Ariane Aigelsreiter, Daniela Schwarzenbacher

|Mar 10, 2017
Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.

G Richtig, C Hoeller, K Kashofer

Pageof 3

Frequent Collaborators

2 joint publications

Lukas Koch

1 joint publications

T Deinlein

1 joint publications

Gerald Hoefler

1 joint publications

Matthew Dankner